Category: Anaemic Hypoxia

Anaemic Hypoxia – Anaemic.net

The Nobel Prize in Physiology or Medicine 2019

EnglishEnglish (pdf)SwedishSwedish (pdf)[1][2][3] 2019-10-07 The Nobel Assembly at Karolinska Institutet[4] has today decided to award the 2019 Nobel Prize in Physiology or Medicine jointly to William G. Kaelin Jr., Sir Peter J. Ratcliffe and Gregg L. Semenza for their discoveries of how cells sense and adapt to oxygen availability SUMMARY Animals need oxygen for the conversion of food into useful...

READ MORE The Nobel Prize in Physiology or Medicine 2019

GSK submits first regulatory application for daprodustat in Japan for patients with renal anaemia due to chronic kidney disease

Issued: London, UK GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a Japanese New Drug Application (JNDA) to the Ministry of Health, Labour and Welfare seeking marketing approval for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with renal anaemia due to chronic kidney disease (CKD). Dr Hal Barron, Chief Scientific Officer and...

READ MORE GSK submits first regulatory application for daprodustat in Japan for patients with renal anaemia due to chronic kidney disease

GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease

For media and investors only Issued: London, UK Approval marks a significant step in GSK’s global efforts to help patients with anaemia due to chronic kidney disease (CKD). GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the approval of a Japanese New Drug Application (JNDA) by the Ministry of Health, Labour and Welfare for Duvroq (daprodustat) tablets, an oral hypoxia-inducible factor prolyl...

READ MORE GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease

Sanofi: Press Releases, Tuesday, December 10, 2019

Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease Sutimlimab, a novel investigational C1s inhibitor, has the potential to be the first approved treatment for cold agglutinin disease, a serious, chronic, rare blood disorder Results met the primary and secondary endpoints and demonstrated rapid inhibition of hemolysis and clinically significant improvements in anemia...

READ MORE Sanofi: Press Releases, Tuesday, December 10, 2019

Generated by Feedzy